Shire/Baxalta Merger's Benefits Doubted By Wall Street
This article was originally published in The Pink Sheet Daily
Although Shire struggled toward this merger for five months and says it will position Shire as the top rare disease company in the world, analysts question the long-term viability of Baxalta's hemophilia franchise and whether the total benefits warrant the price being paid.
You may also be interested in...
The rare disease specialist’s new CEO is former Baxalta CEO Ludwig Hantson, who takes over the helm immediately after a leadership shakeup coinciding with an audit investigation.
Cardio Conversations: ‘Much More Than Just A Patch,’ iRhythm CEO Blackford Talks AI Arrhythmia Diagnostics
iRhythm CEO Quentin Blackford returned to Medtech Insight’s Cardio Conversations podcast to talk about the launch of his company’s new Zio monitor patch supported by a sophisticated neural network. He also addressed the company’s plans to improve its position in the mobile cardiac telemetry market, the impact of pulsed field ablation on the cardiac monitoring business, and more.
In this week's podcast edition of Five Must-Know Things: optimistic outlook for biopharma IPOs; Boehringer’s promising MASH results; Viking emerges as obesity contender; Incyte looks to portfolio diversification; and a look at China’s HPV vaccine market.